Concerns about HAART (Highly Active Anti-Retroviral Therapy)

Alberta Reappraising AIDS Society

David R. Crowe, President
Phone: +1-403-289-6609
Fax: +1-403-206-7717
Email: David.Crowe@aras.ab.ca

Roger Swan, Treasurer
Box 61037, Kensington Postal Outlet
Calgary, Alberta T2N 4S6
Canada
Office
Phone: +1-403-220-0129
Email: aras@aras.ab.ca
Web: noaids.ca

Concerns about HAART (Highly Active Anti-Retroviral Therapy)

Concerns about HAART (Highly Active Anti-Retroviral Therapy)

HAART is the therapy, composed of three or four drugs that are claimed to attack HIV. This so-called 'cocktail' is prescribed to many HIV-positive people, even before they develop symptoms of AIDS (and without considering that many will never develop these symptoms). The therapy usually includes one or two nucleoside analogs (DNA chain terminator), and often one or two protease inhbitors or drugs in other classes such as NNRTIs and fusion inhibitors.

The quotes are categorized as:

  • Acceptance
  • Adherence/Compliance
  • Other Adverse Effects
  • Adverse Effects with Nucleoside Analogs (‘Nukes’)
  • Auxiliary Therapy
  • Blood Disorders (Anemia etc.)
  • Bone Disease
  • Cancer
  • Drug company disclaimers
  • Heart Disease
  • Ineffectiveness
  • Immune Restitution Disease (IRD) or Immune Restoration Inflammatory Syndrome (IRIS)
  • Kidney Damage (Nephrotoxicity)
  • Liver Damage
  • HAART for a Life Time (not a Good Time)?
  • Metabolic Disorders
  • Mitochondria
  • Muscle Damage
  • Neurological and Brain Damage
  • Nevirapine
  • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
  • Non-HIV Benefits of HAART
  • Health Without Toxic Therapies
  • Post-Exposure Prophylaxis (PEP)
  • Mothers & Children
  • Protease Inhibitors
  • Resistance to Therapy
  • Rashes and Other Skin Problems
  • Usage Trends
  • Feedback

    We appreciate your comments, feedback, questions and suggestions for improvements to this site. Click here to send us a message.

    © Copyright February 15, 2016: Alberta Reappraising AIDS Society